Financial News
Press Releases about Immunitybio Inc
![](https://mms.businesswire.com/media/20240620264106/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240607246847/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240516520260/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240507050323/en/2122218/22/I05.07.2024_-_mmunityBio-Dunkirk-New-York-GMP-Manufacturing-Facility%5B1%5D.jpg)
![](https://mms.businesswire.com/media/20240502530543/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240430306875/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240424428572/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240422820209/en/2106251/5/Carton-%26-Vial.jpg)
![](https://www.marketbeat.com/logos/articles/med_20240307141801_5-stocks-with-unusually-large-short-interest.jpg)
![](https://mms.businesswire.com/media/20240306651162/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240305877538/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240221666790/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://www.marketbeat.com/logos/articles/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg)
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
Via MarketBeat
Topics
Artificial Intelligence
![](https://mms.businesswire.com/media/20240205300717/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20240102781220/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20231116785447/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
From ImmunityBio, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20231107571659/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20231026155505/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
From ImmunityBio, Inc.
Via Business Wire
![](https://mms.businesswire.com/media/20231023256922/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20230911111993/en/1463552/22/BusinessWire_-ImmunityBio.jpg)
![](https://mms.businesswire.com/media/20230829525364/en/1164042/5/July_30%2C_2021_-_ROSEN_LOGO.jpg)
![](https://mms.businesswire.com/media/20230828617957/en/765953/22/Close_Up_Logo_HD_Blue.jpg)
NASDAQ:IBRX Investor Notice: Deadline on August 29, 2023 in Lawsuit Against ImmunityBio, Inc.
August 28, 2023
Via SBWire
Topics
Lawsuit
![](https://www.newmediawire.com/media/sites/270/images/social-image.jpg)
Via NewMediaWire
Topics
Lawsuit
![](https://mms.businesswire.com/media/20230825952230/en/538768/22/BES_Mark.jpg)
Via NewMediaWire
Topics
Lawsuit
![](https://ml.globenewswire.com/media/5d514042-8326-4555-8ad7-f6cc765ecfcd/small/bl-new-logo-jpg.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.